Benveniste Olivier, Goebel Hans-Hilmar, Stenzel Werner
Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital, Assistance Public-Hôpitaux de Paris, Sorbonne-Université, INSERM, UMR974, Paris, France.
Department of Neuropathology, Berlin Institute of Health (BIH), Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Front Neurol. 2019 Jun 4;10:554. doi: 10.3389/fneur.2019.00554. eCollection 2019.
Biomarkers as parameters of pathophysiological conditions can be of outmost relevance for inflammatory myopathies. They are particularly warranted to inform about diagnostic, prognostic, and therapeutic questions. As biomarkers become more and more relevant in daily routine, this review focusses on relevant aspects particularly addressing myopathological features. However, the level of evidence to use them in daily routine at presence is low, still since none of them has been validated in large cohorts of patients and rarely in independent biopsy series. Hence, they should be read as mere expert opinions. The evaluation of biomarkers as well as key biological parameters is an ongoing process, and we start learning about relevance of them, as we must recognize that pathophysiology of myositis is biologically incompletely understood. As such this approach should be considered an essay toward expansion of the definition "biomarker" to myositis, an emerging field of interest in biomedical research.
生物标志物作为病理生理状况的参数,对于炎性肌病可能具有至关重要的意义。它们对于解答诊断、预后和治疗方面的问题尤为必要。随着生物标志物在日常临床中变得越来越重要,本综述聚焦于特别涉及肌病理特征的相关方面。然而,目前在日常临床中使用这些生物标志物的证据水平较低,因为它们中没有一个在大量患者队列中得到验证,在独立活检系列中也很少得到验证。因此,本文应仅作为专家意见来解读。对生物标志物以及关键生物学参数的评估是一个持续的过程,我们开始了解它们的相关性,因为我们必须认识到,肌炎的病理生理学在生物学上尚未完全明了。因此,这种方法应被视为一篇旨在将“生物标志物”的定义扩展到肌炎领域的文章,这是生物医学研究中一个新兴的关注领域。